Dr Tony Radford
Tony Radford was the co-founder and CEO of Cellestis which developed and commercialised QuantiFERON Gold, for diagnosis of tuberculosis infection. Cellestis listed on the ASX and was acquired by QIAGEN NV in 2011 for approximately $400M.
Tony has a PhD from La Trobe University, and was awarded an Order of Australia for distinguished service to science and global public health. Tony is a director of Genetic Signalures (ASX: GSS).